Last reviewed · How we verify

Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE]

Ain Shams University · Phase 1 active Small molecule Quality 0/100

Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE] is a Small molecule drug developed by Ain Shams University. It is currently in Phase 1 development. Also known as: Xylocaine 2%.

At a glance

Generic nameLidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE]
Also known asXylocaine 2%
SponsorAin Shams University
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE]

What is Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE]?

Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE] is a Small molecule drug developed by Ain Shams University.

Who makes Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE]?

Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE] is developed by Ain Shams University (see full Ain Shams University pipeline at /company/ain-shams-university).

Is Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE] also known as anything else?

Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE] is also known as Xylocaine 2%.

What development phase is Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE] in?

Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE] is in Phase 1.

Related